EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #72902_C
表观遗传修饰剂;抑制DNA甲基转移酶（DNMT）
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
总览
Zebularine是胞苷类似物，一种DNA甲基化抑制剂，通过与DNA甲基转移酶（DNMT）形成共价复合物发挥作用（Zhou et al.）。
分化
·可诱导大鼠骨髓间充质干细胞（MSCs）向心肌细胞分化（Naeem et al.）。
癌症研究
·可减少癌细胞系TK6、Jurkat、KG-1和HCT116的增殖（Stresemann et al.）。
·抑制T24膀胱癌细胞增殖（Ben-Kasus et al.）。
·与组蛋白去乙酰化酶抑制剂SAHA一起使用，可减少胰腺癌细胞系中的细胞增殖，增加细胞凋亡（Neureiter et al.）。
·体外抑制人急性髓系白血病细胞增殖并诱导细胞凋亡（Scott et al.）。
·增加人癌细胞和肝癌细胞系亚群中具有癌症干细胞特性的细胞比例（Marquardt et al.）。
细胞类型
癌细胞及细胞系，心肌细胞，PSC衍生，白血病/淋巴瘤细胞，间充质干/祖细胞
种属
人，小鼠，非人灵长类，其它细胞系，大鼠
应用
分化
研究领域
癌症，干细胞生物学
CAS 编号
3690-10-6
化学式
C₉H₁₂N₂O₅
纯度
≥98%
通路
表观遗传学
靶点
DNMT
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (3)
文献 (9)
DNA methylation inhibitors, 5-azacytidine and zebularine potentiate the transdifferentiation of rat bone marrow mesenchymal stem cells into cardiomyocytes. Cardiovascular therapeutics 2013 AUG
Abstract
BACKGROUND Mesenchymal stem cells (MSCs) have immense self-renewal capability. They can be differentiated into many cell types and therefore hold great potential in the field of regenerative medicine. MSCs can be converted into beating cardiomyocytes by treating them with DNA-demethylating agents. Some of these compounds are nucleoside analogs that are widely used for studying the role of DNA methylation in biological processes as well as for the clinical treatment of leukemia and other carcinomas. AIMS To achieve a better therapeutic option for cardiovascular regeneration, this study was carried out using MSCs treated with two synthetic compounds, zebularine and 5-azacytidine. It can be expected that treated MSCs prior to transplantation may increase the likelihood of successful regeneration of damaged myocardium. METHODS The optimized concentrations of these compounds were added separately into the culture medium and the treated cells were analyzed for the expression of cardiac-specific genes by RT-PCR and cardiac-specific proteins by immunocytochemistry and flow cytometry. Treated MSCs were cocultured with cardiomyocytes to see the fusion capability of these cells. RESULTS mRNA and protein expressions of GATA4, Nkx2.5, and cardiac troponin T were observed in the treated MSCs. Coculture studies of MSCs and cardiomyocytes have shown improved fusion with zebularine-treated MSCs as compared to untreated and 5-azacytidine-treated MSCs. CONCLUSION The study is expected to put forth another valuable aspect of certain compounds, that is, induction of transdifferentiation of MSCs into cardiomyocytes. This would serve as a tool for modified cellular therapy and may increase the probability of better myocardial regeneration.
Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology (Baltimore, Md.) 2011 SEP
Abstract
UNLABELLED Epigenetic mechanisms play critical roles in stem cell biology by maintaining pluripotency of stem cells and promoting differentiation of more mature derivatives. If similar mechanisms are relevant for the cancer stem cell (CSC) model, then epigenetic modulation might enrich the CSC population, thereby facilitating CSC isolation and rigorous evaluation. To test this hypothesis, primary human cancer cells and liver cancer cell lines were treated with zebularine (ZEB), a potent DNA methyltransferase-1 inhibitor, and putative CSCs were isolated using the side population (SP) approach. The CSC properties of ZEB-treated and untreated subpopulations were tested using standard in vitro and in vivo assays. Whole transcriptome profiling of isolated CSCs was performed to generate CSC signatures. Clinical relevance of the CSC signatures was evaluated in diverse primary human cancers. Epigenetic modulation increased frequency of cells with CSC properties in the SP fraction isolated from human cancer cells as judged by self-renewal, superior tumor-initiating capacity in serial transplantations, and direct cell tracking experiments. Integrative transcriptome analysis revealed common traits enriched for stemness-associated genes, although each individual CSC gene expression signature exhibited activation of different oncogenic pathways (e.g., EGFR, SRC, and MYC). The common CSC signature was associated with malignant progression, which is enriched in poorly differentiated tumors, and was highly predictive of prognosis in liver and other cancers. CONCLUSION Epigenetic modulation may provide a tool for prospective isolation and in-depth analysis of CSC. The liver CSC gene signatures are defined by a pernicious interaction of unique oncogene-specific and common stemness traits. These data should facilitate the identifications of therapeutic tools targeting both unique and common features of CSCs.
Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine. PloS one 2010 JAN
Abstract
In mammals DNA methylation occurs at position 5 of cytosine in a CpG context and regulates gene expression. It plays an important role in diseases and inhibitors of DNA methyltransferases (DNMTs)--the enzymes responsible for DNA methylation--are used in clinics for cancer therapy. The most potent inhibitors are 5-azacytidine and 5-azadeoxycytidine. Zebularine (1-(beta-D-ribofuranosyl)-2(1H)- pyrimidinone) is another cytidine analog described as a potent inhibitor that acts by forming a covalent complex with DNMT when incorporated into DNA. Here we bring additional experiments to explain its mechanism of action. First, we observe an increase in the DNA binding when zebularine is incorporated into the DNA, compared to deoxycytidine and 5-fluorodeoxycytidine, together with a strong decrease in the dissociation rate. Second, we show by denaturing gel analysis that the intermediate covalent complex between the enzyme and the DNA is reversible, differing thus from 5-fluorodeoxycytidine. Third, no methylation reaction occurs when zebularine is present in the DNA. We confirm that zebularine exerts its demethylation activity by stabilizing the binding of DNMTs to DNA, hindering the methylation and decreasing the dissociation, thereby trapping the enzyme and preventing turnover even at other sites.
更多信息
| 种属 | Human, Mouse, Non-Human Primate, Other, Rat |
|---|---|
| Cas Number | 3690-10-6 |
| Chemical Formula | C₉H₁₂N₂O₅ |
| 纯度 | ≥ 98% |
| Target | DNMT |
| Pathway | Epigenetic |
相关产品
-
ALDEFLUOR™工具用于鉴定、评估和分离表达高水平ALDH的干细胞和祖细胞
-
5-氮杂胞苷（5-Azacytidine）表观遗传修饰剂；抑制 DNA 甲基转移酶 (DNMT)
-
RG108表观遗传修饰剂；抑制 DNA 甲基转移酶 (DNMT)
-
RSC-133表观遗传修饰剂；抑制 DNA 甲基转移酶 (DNMT)
